English 
Japanese 
Latest news
- May 23, 2025Eisai to Present E7386, Co-created by PRISM BioLab and Eisai, at the ASCO (American Society of Clinical Oncology) Annual Meeting
- May 14, 2025Announcement: Investor Relations Seminar for Individual Investors
- May 10, 2025Featured in Nikkei Biotech
- April 14, 2025Featured in The Nikkei
- April 13, 2025PRISM BioLab and Elix Join Forces to Accelerate AI-Driven Drug Discovery for Protein-Protein Interaction Targets
Latest News
- Eisai to Present E7386, Co-created by PRISM BioLab and Eisai, at the ASCO (American Society of Clinical Oncology) Annual Meeting
- Announcement: Investor Relations Seminar for Individual Investors
- Featured in Nikkei Biotech
- Featured in The Nikkei
- PRISM BioLab and Elix Join Forces to Accelerate AI-Driven Drug Discovery for Protein-Protein Interaction Targets
- Announcement: Guest Appearance on Radio NIKKEI 1’s The Money – Thursday, Hideaki Sakurai’s Kabutetsu
- Announcement: Participation in LINK-J’s Miyaman’s Venture Talk vol.12
- Announcement of Appointment and Resignation of Directors
- Our CEO Takahara Featured on “IRTV” Video Media
- Event Report: CTO Toma Speaks at LINK-J and Merck Co-hosted Symposium
About
PRISM BIOLAB
MISSION:
PRISM BioLab is committed to maximizing the potential of its PepMetics® Technology, transforming the “undruggable” to “druggable” with the aim of finding cures for the incurable.
PRISM BioLab is a biotechnology company with PepMetics Technology, a proprietary drug discovery platform. PepMetics Molecules are designed to mimic α-helix or β-turn peptides using unique, stable scaffolds.
PepMetics
Technology
We synthesize like a small molecule, but our PepMetic Molecules act like peptides.
Peptide
MIMETICS
“PepMetics”®
LIBRARY
PRISM’s PepMetics Real Library includes 20,000+ compounds covering various amino acid sequences for screening. The PepMetics Library is used to generate hits for difficult targets.
